JP2009507876A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009507876A5 JP2009507876A5 JP2008530426A JP2008530426A JP2009507876A5 JP 2009507876 A5 JP2009507876 A5 JP 2009507876A5 JP 2008530426 A JP2008530426 A JP 2008530426A JP 2008530426 A JP2008530426 A JP 2008530426A JP 2009507876 A5 JP2009507876 A5 JP 2009507876A5
- Authority
- JP
- Japan
- Prior art keywords
- mol
- mochol
- popc
- dope
- dmgsucc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 21
- 239000002502 liposome Substances 0.000 claims 18
- -1 anionic lipid Chemical class 0.000 claims 13
- 108091034117 Oligonucleotide Proteins 0.000 claims 11
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 claims 9
- 150000002632 lipids Chemical class 0.000 claims 7
- 239000013543 active substance Substances 0.000 claims 6
- 108020004999 messenger RNA Proteins 0.000 claims 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 5
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 5
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 101150013553 CD40 gene Proteins 0.000 claims 3
- 108090000994 Catalytic RNA Proteins 0.000 claims 3
- 102000053642 Catalytic RNA Human genes 0.000 claims 3
- 125000002091 cationic group Chemical group 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 108091092562 ribozyme Proteins 0.000 claims 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 108091027757 Deoxyribozyme Proteins 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 claims 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108020004638 Circular DNA Proteins 0.000 claims 1
- 208000014997 Crohn colitis Diseases 0.000 claims 1
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 108091023045 Untranslated Region Proteins 0.000 claims 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 125000005642 phosphothioate group Chemical group 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (25)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71729305P | 2005-09-15 | 2005-09-15 | |
| US71719905P | 2005-09-15 | 2005-09-15 | |
| US71729105P | 2005-09-15 | 2005-09-15 | |
| EP05020216.7 | 2005-09-15 | ||
| US60/717,199 | 2005-09-15 | ||
| US60/717,291 | 2005-09-15 | ||
| EP05020218.3 | 2005-09-15 | ||
| EP05020218 | 2005-09-15 | ||
| EP05020216A EP1764089A1 (en) | 2005-09-15 | 2005-09-15 | Serum stable liposomes comprising amphoter II lipid mixtures |
| EP05020217A EP1764090A1 (en) | 2005-09-15 | 2005-09-15 | Amphoteric liposomes for local drug applications |
| US60/717,293 | 2005-09-15 | ||
| EP05020217.5 | 2005-09-15 | ||
| US11/266,999 US20060216343A1 (en) | 2004-11-05 | 2005-11-04 | Pharmaceutical compositions comprising an oligonucleotide as an active agent |
| PCT/EP2005/011905 WO2006048329A1 (en) | 2004-11-05 | 2005-11-04 | Improvements in or relating to pharmaceutical compositions comprising an oligonucleotide as an active agent |
| EPPCT/EP2005/011908 | 2005-11-04 | ||
| US11/267,423 | 2005-11-04 | ||
| US11/267,423 US20060159737A1 (en) | 2004-11-19 | 2005-11-04 | Pharmaceutical compositions for local administration |
| EPPCT/EP2005/011905 | 2005-11-04 | ||
| US11/266,999 | 2005-11-04 | ||
| PCT/EP2005/011908 WO2006053646A2 (en) | 2004-11-19 | 2005-11-04 | Improvements in or relating to pharmaceutical compositions for local administration |
| EP05090322A EP1658839A1 (en) | 2004-11-05 | 2005-11-21 | Oligonucleotide/carrier combinations targeting CD40 |
| EP05090322.8 | 2005-11-21 | ||
| EP06113784 | 2006-05-10 | ||
| EP06113784.0 | 2006-05-10 | ||
| PCT/EP2006/009013 WO2007031333A2 (en) | 2005-09-15 | 2006-09-15 | Improvements in or relating to amphoteric liposomes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009507876A JP2009507876A (ja) | 2009-02-26 |
| JP2009507876A5 true JP2009507876A5 (https=) | 2009-11-12 |
| JP5571308B2 JP5571308B2 (ja) | 2014-08-13 |
Family
ID=37631866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008530426A Active JP5571308B2 (ja) | 2005-09-15 | 2006-09-15 | 両性リポソームにおけるまたはそれに関する改善 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20070104775A1 (https=) |
| EP (1) | EP1764091B1 (https=) |
| JP (1) | JP5571308B2 (https=) |
| KR (1) | KR20080082956A (https=) |
| AU (1) | AU2006291429B2 (https=) |
| CA (2) | CA2889540A1 (https=) |
| WO (1) | WO2007031333A2 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10109897A1 (de) * | 2001-02-21 | 2002-11-07 | Novosom Ag | Fakultativ kationische Liposomen und Verwendung dieser |
| US8815599B2 (en) | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
| KR20080082956A (ko) | 2005-09-15 | 2008-09-12 | 노보솜 아게 | 양쪽성 리포솜의 개선 또는 양쪽성 리포솜에 관련된 개선 |
| CA2631677C (en) * | 2005-12-01 | 2014-08-12 | Pronai Therapeutics, Inc. | Amphoteric liposome formulation |
| EP2004141A2 (en) * | 2006-03-17 | 2008-12-24 | Novosom AG | An efficient method for loading amphoteric liposomes with nucleic acid active substances |
| JP5118139B2 (ja) * | 2006-08-04 | 2013-01-16 | バクスター・インターナショナル・インコーポレイテッド | 新規発症自己免疫性糖尿病を予防および／または逆転させるためのマイクロスフィアに基づく組成物 |
| JP5424885B2 (ja) | 2006-10-13 | 2014-02-26 | マリーナ バイオテック，インコーポレイテッド | 両性リポソームにおけるまたは両性リポソームに関する改善、両性リポソームを処方する方法および両性リポソームに充填する方法 |
| WO2008103431A2 (en) * | 2007-02-23 | 2008-08-28 | Pronai Therapeutics, Inc. | Dnai - liposomes |
| GB0719367D0 (en) | 2007-10-03 | 2007-11-14 | Procarta Biosystems Ltd | Transcription factor decoys, compositions and methods |
| CA2702103A1 (en) * | 2007-10-12 | 2009-04-16 | Novosom Ag | Improvements in or relating to amphotaric liposomes comprising neutral lipids |
| US9186343B2 (en) * | 2007-12-26 | 2015-11-17 | Nanoveson, Llc | Nanoveso™: treatment, biomarkers and diagnostic tests for liver diseases and comorbid diseases |
| CN102112110A (zh) * | 2008-06-06 | 2011-06-29 | 米尔纳医疗股份有限公司 | 用于RNAi试剂体内递送的新型组合物 |
| JP5588619B2 (ja) * | 2009-03-11 | 2014-09-10 | 一丸ファルコス株式会社 | ｐＨ応答性リポソーム |
| US9937128B2 (en) * | 2009-08-03 | 2018-04-10 | The University Of North Carolina At Chapel Hill | Liposomes comprising a calcium phosphate-containing precipitate |
| GB201002413D0 (en) * | 2010-02-12 | 2010-03-31 | Procarta Biosystems Ltd | Nucleic acid complexes |
| GB201005545D0 (en) | 2010-04-01 | 2010-05-19 | Procarta Biosystems Ltd | Transcription factor decoys |
| IT1404011B1 (it) | 2010-12-03 | 2013-11-08 | Uni Degli Studi Magna Graecia Di Catanzaro | Nanovettore coniugato con tsh per il trattamento del cancro della tiroide |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| RU2677658C2 (ru) | 2012-07-05 | 2019-01-18 | Тайвэн Липосом Ко, Лтд. | Способы лечения артрита |
| KR20160127828A (ko) * | 2014-03-12 | 2016-11-04 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 리포솜 제형 |
| CN108064175A (zh) | 2014-08-04 | 2018-05-22 | 米拉根医疗股份有限公司 | Myh7b的抑制剂及其用途 |
| AU2015315298B2 (en) | 2014-09-08 | 2020-05-14 | MiRagen Therapeutics, Inc. | miR-29 mimics and uses thereof |
| US9885042B2 (en) | 2015-01-20 | 2018-02-06 | MiRagen Therapeutics, Inc. | miR-92 inhibitors and uses thereof |
| MX368314B (es) | 2015-06-05 | 2019-09-27 | Miragen Therapeutics Inc | Inhibidores del mir-155 para tratar linfoma cutáneo de células t (ctcl). |
| CN115404196A (zh) | 2016-07-13 | 2022-11-29 | 哈佛学院院长等 | 抗原呈递细胞模拟支架及其制备和使用方法 |
| BR112019024505A2 (pt) * | 2017-05-23 | 2020-06-23 | Tci Co., Ltd. | Composição de lipossoma emulsionada e processo de preparação da mesma |
| WO2019048645A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | STABILIZED COMPOSITIONS OF SMALL ACTIVATOR RNA (PARNA) FROM CEBPA AND METHODS OF USE |
| EP3775211B1 (en) | 2018-04-12 | 2023-04-05 | MiNA Therapeutics Limited | Sirt1-sarna compositions and methods of use |
| EP3953473A1 (en) | 2019-04-12 | 2022-02-16 | MiNA Therapeutics Limited | Sirt1-sarna compositions and methods of use |
| GB2603454A (en) | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
| EP4314292A1 (en) | 2021-03-26 | 2024-02-07 | MiNA Therapeutics Limited | Tmem173 sarna compositions and methods of use |
| JP7761921B2 (ja) * | 2021-05-21 | 2025-10-29 | 国立大学法人北海道大学 | 脂質ナノ粒子 |
| US20230181644A1 (en) | 2021-10-28 | 2023-06-15 | Lyell Immunopharma, Inc. | Methods of generating cells |
| WO2023099884A1 (en) | 2021-12-01 | 2023-06-08 | Mina Therapeutics Limited | Pax6 sarna compositions and methods of use |
| GB202117758D0 (en) | 2021-12-09 | 2022-01-26 | Ucl Business Ltd | Therapeutics for the treatment of neurodegenerative disorders |
| WO2023170435A1 (en) | 2022-03-07 | 2023-09-14 | Mina Therapeutics Limited | Il10 sarna compositions and methods of use |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024125597A1 (en) | 2022-12-14 | 2024-06-20 | Providence Therapeutics Holdings Inc. | Compositions and methods for infectious diseases |
| WO2024134199A1 (en) | 2022-12-22 | 2024-06-27 | Mina Therapeutics Limited | Chemically modified sarna compositions and methods of use |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
| WO2026006604A1 (en) | 2024-06-26 | 2026-01-02 | Lyell Immunopharma, Inc. | Feeder cell replacement |
| WO2026027887A2 (en) | 2024-08-02 | 2026-02-05 | Mina Therapeutics Limited | Hbg1/2-sarna compositions and methods of use |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077211A (en) * | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| ATE209887T1 (de) * | 1993-04-02 | 2001-12-15 | Anticancer Inc | Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel |
| US5834012A (en) * | 1995-05-03 | 1998-11-10 | Roman Perez-Soler | Lipid complexed topoisomerase I inhibitors |
| JPH09248182A (ja) * | 1996-03-15 | 1997-09-22 | Oyo Seikagaku Kenkyusho | プラスミド包埋多重膜リポソーム |
| DE19648625A1 (de) | 1996-11-13 | 1998-05-14 | Soft Gene Gmbh | Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer |
| NZ500694A (en) * | 1997-04-30 | 2001-09-28 | Univ Minnesota | Use of chimeric mutational vector (CMV), a macromolecule and a ligand for cell surface receptor adhesion molecule (clatherin) in gene therapy; the CMV vector derived from REC2 homologous pairing with Ustilago maydis |
| CA2289702C (en) * | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US20040186071A1 (en) * | 1998-04-13 | 2004-09-23 | Bennett C. Frank | Antisense modulation of CD40 expression |
| US6197584B1 (en) * | 1998-05-01 | 2001-03-06 | Isis Pharmaceuticals, Inc. | Antisense modulation of CD40 expression |
| US6897200B1 (en) * | 1998-10-14 | 2005-05-24 | University Of Kentucky Research Foundation | Oligonucleotide delivery systems for camptothecins |
| US6379698B1 (en) * | 1999-04-06 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Fusogenic lipids and vesicles |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| DE10109898A1 (de) | 2001-02-21 | 2002-09-05 | Novosom Gmbh | Lipide mit veränderlicher Ladung |
| DE10109897A1 (de) * | 2001-02-21 | 2002-11-07 | Novosom Ag | Fakultativ kationische Liposomen und Verwendung dieser |
| EP1361862B1 (en) * | 2001-02-22 | 2007-04-18 | Opperbas Holding B.V. | Liposome-mediated dna administration |
| ATE490267T1 (de) | 2001-06-05 | 2010-12-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt, kodierend für ein virales antigen |
| DE10207178A1 (de) | 2002-02-19 | 2003-09-04 | Novosom Ag | Komponenten für die Herstellung amphoterer Liposomen |
| DE10207177A1 (de) | 2002-02-19 | 2003-09-04 | Novosom Ag | Fakultativ kationische Lipide |
| WO2003097805A2 (en) * | 2002-05-15 | 2003-11-27 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
| AU2002953285A0 (en) * | 2002-12-12 | 2003-01-02 | Protech Research Pty Ltd | Yeast treatment |
| AU2004227414A1 (en) | 2003-04-03 | 2004-10-21 | Alnylam Pharmaceuticals | iRNA conjugates |
| ES2559828T3 (es) * | 2003-07-16 | 2016-02-16 | Protiva Biotherapeutics Inc. | ARN de interferencia encapsulado en lípidos |
| EP1807050A1 (en) * | 2004-11-05 | 2007-07-18 | Novosom AG | Improvements in or relating to pharmaceutical compositions comprising an oligonucleotide as an active agent |
| EP1811960A2 (en) * | 2004-11-19 | 2007-08-01 | Novosom AG | Improvements in or relating to pharmaceutical compositions for local administration |
| EP1764090A1 (en) | 2005-09-15 | 2007-03-21 | Novosom AG | Amphoteric liposomes for local drug applications |
| EP1764089A1 (en) | 2005-09-15 | 2007-03-21 | Novosom AG | Serum stable liposomes comprising amphoter II lipid mixtures |
| KR20080082956A (ko) * | 2005-09-15 | 2008-09-12 | 노보솜 아게 | 양쪽성 리포솜의 개선 또는 양쪽성 리포솜에 관련된 개선 |
-
2006
- 2006-09-15 KR KR1020087008987A patent/KR20080082956A/ko not_active Withdrawn
- 2006-09-15 EP EP06254821.9A patent/EP1764091B1/en active Active
- 2006-09-15 JP JP2008530426A patent/JP5571308B2/ja active Active
- 2006-09-15 US US11/521,857 patent/US20070104775A1/en not_active Abandoned
- 2006-09-15 WO PCT/EP2006/009013 patent/WO2007031333A2/en not_active Ceased
- 2006-09-15 CA CA2889540A patent/CA2889540A1/en not_active Abandoned
- 2006-09-15 CA CA2622584A patent/CA2622584C/en active Active
- 2006-09-15 AU AU2006291429A patent/AU2006291429B2/en active Active
-
2010
- 2010-09-09 US US12/807,707 patent/US9066867B2/en active Active
-
2014
- 2014-11-12 US US14/538,809 patent/US9737484B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009507876A5 (https=) | ||
| Zhu et al. | RNA-based therapeutics: an overview and prospectus | |
| CA2622584A1 (en) | Improvements in or relating to amphoteric liposomes | |
| JP4951338B2 (ja) | 脂質に封入された干渉ｒｎａ | |
| ES2960939T3 (es) | Agentes crioprotectores para formulaciones particuladas | |
| CN113166783B (zh) | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 | |
| CN103906504B (zh) | 制备用于药物递送的脂质纳米颗粒的方法 | |
| US20070135370A1 (en) | siRNA silencing of filovirus gene expression | |
| JP7843707B2 (ja) | 肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質 | |
| TW201900876A (zh) | 用於使b型肝炎病毒基因表現靜默之組成物及方法 | |
| JPWO2022040641A5 (https=) | ||
| KR20240072931A (ko) | 히스티딘을 포함하는 지질 나노입자 및 그 제조방법 | |
| Katas et al. | Bionanocomposites for RNAi-based delivery | |
| KR20240118489A (ko) | 단일 용기를 이용하는 유기 용매를 사용하지 않는 열순환기법에 의한 핵산 전달용 지질나노입자의 제조방법 | |
| CN121197094A (zh) | 一种花生四烯酸脂质纳米递药系统 | |
| HK40052154A (en) | Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto | |
| Walsh | Design, Synthesis, and Characterization of Novel Zwitterionic Lipids for Drug and siRNA Delivery Applications | |
| MacLachlan | Lipid-Mediated in vivo Delivery of Small Interfering RNAs |